New KRAS Inhibitor Daraxonrasib Offers Hope for Pancreatic Cancer Patients
In April 2026, a clinical trial patient with metastatic pancreatic cancer experienced prolonged survival after receiving daraxonrasib, a novel KRAS G12C inhibitor developed by Revolution Medicines, marking a significant advancement ... Read More